Cargando…
Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
INTRODUCTION: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small m...
Autores principales: | Zechmann, Christian M., Afshar-Oromieh, Ali, Armor, Tom, Stubbs, James B., Mier, Walter, Hadaschik, Boris, Joyal, John, Kopka, Klaus, Debus, Jürgen, Babich, John W., Haberkorn, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052014/ https://www.ncbi.nlm.nih.gov/pubmed/24577951 http://dx.doi.org/10.1007/s00259-014-2713-y |
Ejemplares similares
-
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017) -
Preliminary evaluation of prostate‐targeted radiotherapy using (131)I‐MIP‐1095 in combination with radiosensitising chemotherapeutic drugs
por: Tesson, Mathias, et al.
Publicado: (2016) -
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018) -
Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer
por: Giesel, F. L., et al.
Publicado: (2016) -
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2013)